Biosimilars | Specialty

The OncLive Biosimilars condition center page is a comprehensive resource for clinical news and expert insights on currently available and investigational biosimilars for reference drugs such as trastuzumab, rituximab, bevacizumab, and more. This page features news articles, interviews in written and video format, and podcasts that focus on updates with biosimilars and ongoing research with these types of agents.

Dr. Tripathy on the Importance of Biosimilars in Oncology

July 26th 2018

Debu Tripathy, MD, professor and chairman, Department of Breast Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, discusses the importance of biosimilars in oncology.

FDA Approves Second Filgrastim Biosimilar

July 23rd 2018

The FDA approved filgrastim-aafi (Nivestym), a filgrastim (Neupogen) biosimilar, to prevent and treat side effects associated with cancer treatment, including febrile neutropenia and severe neutropenia.

Biosimilar Uptake in Oncology Faces Many Hurdles

July 17th 2018

Carina Dolan, PharmD, BCOP, discusses the factors that impact the successful uptake of biosimilars in the practice of oncology.

Expert Sees Biosimilars as Integral to Expanding Access, Controlling Costs in Oncology

July 17th 2018

Yelena Novik, MD, shares her thoughts on the use of biosimilars in oncology and their potential impact on practice.

Lead Author Reflects on LILAC Study of Trastuzumab Biosimilar ABP 980

July 13th 2018

Hans-Christian Kolberg, MD, discusses ABP 980 and the future of biosimilars in oncology.

Dr. Kolberg Provides a Global Perspective on Biosimilar Integration

July 13th 2018

Hans-Christian Kolberg, MD, head, Department of Obstetrics and Gynecology, Breast Cancer Center, and Gynecologic Cancer Center at Marienhospital Bottrop, Klinik für Gynäkologie und Geburtshilfe, provides a global perspective on the integration of biosimilars into cancer care.

Dr. Novik on the Potential Impact of Biosimilars on Cancer Treatment

July 12th 2018

Yelena Novik, MD, associate professor, New York University’s Perlmutter Cancer Center, discusses the potential impact of biosimilars on the treatment of cancer.

Dr. Herbst on the Bevacizumab Biosimilar in Lung Cancer

July 11th 2018

Roy S. Herbst, MD, PhD, professor of Medicine, chief of Medical Oncology, Yale Cancer Center and Smilow Cancer Hospital, discusses the bevacizumab (Avastin) biosimilar in lung cancer.

Dr. Yardley on the Role of Biosimilars in Breast Cancer

July 3rd 2018

Denise A. Yardley, MD, senior investigator of breast cancer research, Sarah Cannon Research Institute, discusses the role of biosimilars in the treatment of patients with breast cancer.

Expert Highlights Evolution of Biosimilars in Oncology

June 29th 2018

Michael Savin, MD, discusses the emergence of biosimilars in oncology, and why there are still obstacles with incorporating them into clinical practice.

Dr. Novik on the Sustainability of Drug Development

June 29th 2018

Yelena Novik, MD, associate professor, New York University Langone’s Perlmutter Cancer Center, discusses the sustainability of drug development in oncology.

Dr. Kolberg Explains the Approval Process for Biosimilars

June 28th 2018

Hans-Christian Kolberg, MD, head, Department of Obstetrics and Gynecology, Breast Cancer Center, and Gynecologic Cancer Center at Marienhospital Bottrop, Klinik für Gynäkologie und Geburtshilfe, Bottrop, Germany, explains the approval process for biosimilars.

EU Prescribing Patterns for Rituximab Biosimilars in Non-Hodgkin Lymphoma

June 28th 2018

European patients with non-Hodgkin lymphoma are more likely to be prescribed a rituximab biosimilar if they are in better overall health, have indolent histology, and have follicular lymphoma.

Dr. Kwa on the Potential Impact of Biosimilars in Oncology

June 27th 2018

Maryann J. Kwa, MD, instructor, Department of Medicine, NYU Langone’s Perlmutter Cancer Center, discusses the potential impact of biosimilars in oncology.

Dr. Novik on the Adoption of Biosimilars in Breast Cancer

June 23rd 2018

Yelena Novik, MD, associate professor, Department of Medicine, New York University’s Perlmutter Cancer Center, discusses the adoption of biosimilars in breast cancer.

Dr. Kolberg Discusses the Central Pathology Review of ABP 980

June 21st 2018

Hans-Christian Kolberg, MD, head, Department of Obstetrics and Gynecology, Breast Cancer Center, and Gynecologic Cancer Center at Marienhospital Bottrop, Klinik für Gynäkologie und Geburtshilfe, Bottrop, Germany, discusses the central pathology review of the trastuzumab (Herceptin) biosimilar ABP 980.

FDA Strategizes to Step Up Introduction of Lower-Cost Drugs and NGS

June 19th 2018

The market for biosimilar introduction is “extremely unstable,” but the FDA is working to ease the launch of more affordable cancer medicines with a strategy that includes an attempt to reduce anticompetitive behavior.

Dr. Savin on the Evolution of Biosimilars

June 16th 2018

Michael A. Savin, MD, assistant professor of medicine, School of Medicine, Oregon Health and Science University, discusses the evolution of biosimilars.

Dr. Mitri Discusses the Promise of Trastuzumab Biosimilars

June 12th 2018

Zahi Mitri, MD, MS, assistant professor of medicine, Oregon Health and Science University, discusses the promise of trastuzumab (Herceptin) biosimilars.

Dr. Savin Discusses the Future of Biosimilars in Oncology

June 12th 2018

Michael A. Savin, MD, assistant professor of medicine, School of Medicine, Oregon Health and Science University, discusses the future of biosimilars in oncology.